ClinicalTrials.gg
RecruitingNCT06099366SR ALLUpdated Jul 29, 2026

Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children

A Phase 2 interventional study of induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate and Consolidation: Vincristine, Mecaptopurine, Intrathecal Methotrexate in Lymphoblastic Leukemia in Children, sponsored by Hee Young Ju. Recruiting at 13 sites in South Korea. Open to participants aged 1 Year to 9 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Hee Young Ju · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Non-randomized
Ages
1 Year to 9 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 59 studies testing vincristine in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 6 open to participants now, 11 under way, 3 of them phase 3. Vincristine · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Planned enrollment
21st of 59
116 · median 55
Started
2024
with 1 other
Phase 2
27 of 59
4 open now
Primary completion
2033-12
later than 9 of 10 live
Registered
56th of 59
by date

Among the 59 studies testing vincristine in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 21st largest by planned enrollment, is one of 2 that started in 2024, is one of 27 in phase 2, reaches primary completion later than 9 of the 10 other live ones, and was the 56th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

6 of the 59 studies testing vincristine in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About vincristine

Vincristine: first FDA approval 1963 (ONCOVIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 1 Year to 9 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing vincristine in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

Aim of this study is to investigate the outcome of NGS MRD based risk stratified treatment for high risk acute lymphoblastic leukemia in children and adolescents.

03

Conditions studied

  • Lymphoblastic Leukemia in Children

Keywords

  • Standard Risk ALL
  • NGS MRD
04

Who can participate

Ages eligible
1 Year to 9 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

\<Inclusion Criteria>

  • Newly diagnosed pediatric/adolescent acute lymphomblastic leukemia patient with NCL standard risk that stratifies all 1-4 of following

    1. 1 year old ≤ Age \< 10 years old
    2. white blood cell at initial diagnosis \< 5x10\^10/L (50,000uL)
    3. No testis involvement
    4. Satisfaction of following organ functions

A. Kidney function (satisfies i or ii) i. (or radioisotope-measured ) ≥ 70mL/min/1.73m2 ii. Creatinine value according to age/sec satisfies the following:

1 to \< 2 years: Male: 0.6 / Female: 0.6, 2 to \< 6 years: Male: 0.8 / Female: 0.8, 6 to \< 10 years: Male: 1 / Female: 1, 10 to \< 13 years: Male: 1.2 / Female: 1.2, 13 to \< 16 years: Male: 1.5 / Female: 1.4, ≥ 16 years: Male: 1.7 / Female: 1.4 However, subjects who meet the selection criteria within 1 week before registration after receiving appropriate conservative treatment, including fluid therapy, can be registered.

B. Liver function i. Direct \< 3.0mg/dL

\<Exclusion Criteria>

  1. administration within 2 weeks before the registration
  2. t(9;22) or t(4;11)(q11;q23) or chromosome \< 44 or iAMP21 or t(17;19)/TCF3-HLF
  3. Newly diagnosed T cell ALL
  4. One of the following syndromes: Down syndrome, Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome, or other bone marrow failure syndrome
  5. Burkitt leukemia/lymphoma
  6. In the presence of electrocardiographic findings suggesting uncontrolled cardiac dysfunction (e.g., unstable ischemia, symptomatic arrhythmia, congestive heart failure) or congenital long syndrome
  7. When the clinical trial subject(or legal representative) does not consent or is unable to give written consent
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    Standard-low (SL)

    Induction-\> SL Consolidation(4weeks)-\> Interim Maintenance 1st-\> Delayed Intesificaion-\> Interim Maintenance 2nd-\> Maintenance

    Drug: induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate · Drug: Consolidation: Vincristine, Mecaptopurine, Intrathecal Methotrexate · Drug: Interim Maintenance(IM): Vincristine, Methotrexate, Intrathecal Methotrexate · Drug: Delayed Intesification(DI): Vincristine, Mercaptopurine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate · Drug: Maintenance: Vincristine, Mercaptopurine, Methotrexate, Dexamethasone, Intrathecal Methotrexate

  • Experimental
    Standard-average (SA)

    Induction-\> SH Consolidation(4weeks)-\> Intensified Consolidation(4weeks)-\> Interim Maintenance 1st-\> Delayed Intesificaion-\> Interim Maintenance 2nd-\> Maintenance

    Drug: induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate · Drug: Consolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal Methotrexate · Drug: Interim Maintenance(IM): Vincristine, Methotrexate, Intrathecal Methotrexate · Drug: Delayed Intesification(DI): Vincristine, Mercaptopurine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate · Drug: Maintenance: Vincristine, Mercaptopurine, Methotrexate, Dexamethasone, Intrathecal Methotrexate

  • Experimental
    Standard-high 1 (SH1)

    Induction-\> SL Consolidation(4weeks)-\> Intesified Consolidattion(4weeks)-\> Interim Maintenance 1st-\> Delayed Intesificaion 1st-\> Interim Maintenance 2nd-\> Delayed Intestificaion 2nd-\> Maintenance

    Drug: induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate · Drug: Consolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal Methotrexate · Drug: Interim Maintenance(IM): Vincristine, Methotrexate, Mercaptopurine, Intrathecal Methotrexate · Drug: Delayed Intesification(DI): Vincristine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate · Drug: Maintenance: Vincristine, Mercaptopurine, Methotrexate, Dexamethasone, Intrathecal Methotrexate

  • Experimental
    Standard-high 2 (SH2)

    Induction-\> SH Consolidation(4weeks)-\> Intensified Consolidation(4weeks)-\> Interim Maintenance 1st-\> Delayed Intesificaion 1st-\> Interim Maintenance 2nd-\> Delayed Intestificaion 2nd-\> Maintenance

    Drug: induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate · Drug: Consolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal Methotrexate · Drug: Interim Maintenance(IM): Vincristine, Methotrexate, Mercaptopurine, Intrathecal Methotrexate · Drug: Delayed Intesification(DI): Vincristine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate · Drug: Maintenance: Vincristine, Mercaptopurine, Methotrexate, Dexamethasone, Intrathecal Methotrexate

Interventions

06

What researchers measure

Primary outcomes

  1. 5-year event free survival rate

    Time frame: Up to 5-years

Secondary outcomes

  1. Confirmation of the therapeutic effect of the initial treatment response

    Relapse-free survival between two groups(NGS-MRD positive vs. NGS MRD negative after induction) offsets by NGS MRD based stratified treatment

    Time frame: Up to 5-years

  2. Disease prognosis-related factor

    Relapse-free survival according to presence or absence of known good prognosis factors(high hyperdilpoidy, ETV6/RUNX1, Trisomy 4/10/17) have no clinical significance when NGS MRD based stratified treatment is performed.

    Time frame: Up to 5-years

07

Study locations

10 of 13 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2033, 117 months after the start.

Of 209 non-industry phase 2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 120. This study's planned 117 months is above that.

Counting every sponsor, half of 227 studies reached it within 74 months; a quarter within 42 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2023
First posted
Oct 25, 2023
StartActual
Mar 5, 2024
Primary completionEst.
Dec 31, 2033
CompletionEst.
Dec 31, 2033
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06099366
Lead sponsor
Hee Young Ju
Collaborators
Asan Medical Center, Seoul National University Hospital, Seoul St. Mary's Hospital, Severance Hospital, Pusan National University Yangsan Hospital, Korea University Anam Hospital, Chonnam National University Hospital, Jeju National University Hospital, Seoul National University Bundang Hospital, Kyungpook National University Chilgok Hospital, Chungnam National University Hospital, Samsung Medical Center, Ajou University School of Medicine
Responsible party
Hee Young Ju (Clinical Professor, Samsung Medical Center) — Sponsor-investigator
First posted
Oct 25, 2023
Start date
Mar 5, 2024
Primary completion
Dec 31, 2033 (estimated)
Completion
Dec 31, 2033 (estimated)
Last update
Jul 29, 2026

Study contacts

Hee Young Ju, MD, Phd
Contact
heeyoung.ju@samsung.com
82-2-3410-0865
hyunjung Shin
Contact
hjds.shin@samsung.com
82-2-3410-6763

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vincristine · Mercaptopurine · Asparaginase · Doxorubicin · Cyclophosphamide · Cytarabine · Dexamethasone · Methotrexate

Start the discussion